W. Cheema

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab.

David R. Jones, M. Zauderer, C. Rudin, 2021, Cancer discovery.

Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors

S. Solomon, P. Adusumilli, Yasushi Kimura, 2021, Molecular therapy oncolytics.

Tumor and Tumor-Associated Macrophage PD-L1 Expression is Associated with Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.

David R. Jones, W. Travis, K. Tan, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advancing together and moving forward: Combination gene and cellular immunotherapies

P. Adusumilli, S. Priceman, W. Cheema, 2022, Molecular therapy oncolytics.

Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx

David R. Jones, Angela E. Leek, Z. Szallasi, 2023, Nature Medicine.

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.

David R. Jones, M. Zauderer, V. Rusch, 2019, Journal of Clinical Oncology.

Complementary and alternative medicine (CAM) use in cancer patients of immigration background.

Yiqing Xu, R. Hossain, Yunhong Wu, 2021, Journal of Clinical Oncology.

A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients With Esophageal Adenocarcinoma

David R. Jones, V. Rusch, Laura H. Tang, 2023, Annals of surgery.

Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial.

M. Zauderer, M. Maybody, M. Offin, 2022, Lung cancer.